Meeting Banner
Abstract #1043

Diagnostic potential of simultaneous 18 F-FACBC PET/MRI in high risk prostate cancer patients

Kirsten Margrete Selns 1,2 , Mattijs Elschot 1 , Brage Krger-Stokke 1,3 , ystein Strkersen 4 , Dag Linthoe Halvorsen 5 , Elise Sandsmark 1 , May-Britt Tessem 1,2 , Sverre Langrgen 3 , Eirik Kjbli 5 , Anders Angelsen 1 , Frode Willoch 6,7 , Helena Bertilsson 5,8 , Siver Andreas Moestue 1,2 , and Tone Frost Bathen 1,2

1 Department of Sirculation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway, 2 St. Olavs University Hospital, Trondheim, Norway, 3 Clinic of Radiology and Nuclear Medicine, St. Olavs University Hospital, Trondheim, Norway, 4 Clinic of Laboratory Medicine, St. Olavs University Hospital, Trondheim, Norway, 5 Clinic of Surgery, St. Olavs University Hospital, Trondheim, Norway, 6 Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway, 7 Aleris Cancer Center, Oslo, Norway, 8 Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

The leucine amino acid analog 1-amino-3-fluorine 18-fluorocyclobutane-1-carboxylic acid (18F-FACBC) has shown promising results in assessment of primary and metastatic prostate cancer. In the present study a protocol for simultaneous 18F-FACBC PET and multiparametric MR was established and evaluated with respect to the diagnostic potential (N-stage and grade) in high risk prostate cancer patients. The preliminary results show that there is high tracer uptake in regions corresponding to tumor within the gland, however, areas of BPH has also been observed to have high uptake. Histopathologically verified lymph node metastasis also show high uptake of tracer.

This abstract and the presentation materials are available to members only; a login is required.

Join Here